PD-1 blockade in Hodgkin’s lymphoma: learning new tricks from an old teacher
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PD-1 blockade in Hodgkin’s lymphoma: learning new tricks from an old teacher
Authors
Keywords
-
Journal
Expert Review of Hematology
Volume 9, Issue 10, Pages 939-949
Publisher
Informa UK Limited
Online
2016-09-14
DOI
10.1080/17474086.2016.1235970
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalatedPlus Four Cycles of BEACOPPbaselinein Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial
- (2016) Patrice Carde et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine in Combination With Gemcitabine and Vinorelbine Is an Effective Regimen As Induction Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma: Final Results of a Multicenter Phase II Study
- (2016) Armando Santoro et al. JOURNAL OF CLINICAL ONCOLOGY
- Interim Positron Emission Tomography Response–Adapted Therapy in Advanced-Stage Hodgkin Lymphoma: Final Results of the Phase II Part of the HD0801 Study
- (2016) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
- (2016) Margaretha G.M. Roemer et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Role of Cytotoxic Therapy with Hematopoietic Cell Transplantation in the Treatment of Hodgkin Lymphoma: Guidelines from the American Society for Blood and Marrow Transplantation
- (2015) Miguel-Angel Perales et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase I Study of Pembrolizumab (MK-3475; Anti-PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
- (2015) A. Patnaik et al. CLINICAL CANCER RESEARCH
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- PD-1 Restrains Radiotherapy-Induced Abscopal Effect
- (2015) S. S. Park et al. Cancer Immunology Research
- Serum Thymus and Activation-Regulated Chemokine Level Monitoring May Predict Disease Relapse Detected by PET Scan after Reduced-Intensity Allogeneic Stem Cell Transplantation in Patients with Hodgkin Lymphoma
- (2014) Lucia Farina et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
- (2014) Ryan D. Gentzler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
- (2014) T. Bald et al. Cancer Discovery
- The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
- (2013) Andrew M. Evens et al. BRITISH JOURNAL OF HAEMATOLOGY
- Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
- (2013) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Anti-PD1 antibody: a new approach to treatment of lymphomas
- (2013) Emmanuel Bachy et al. LANCET ONCOLOGY
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
- (2013) Jason R Westin et al. LANCET ONCOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
- (2012) Maike Sauer et al. AMERICAN JOURNAL OF HEMATOLOGY
- Autologous Stem Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome
- (2012) Yago Nieto et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
- (2012) M. R. Green et al. CLINICAL CANCER RESEARCH
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial
- (2012) Andreas Engert et al. LANCET
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection
- (2012) Sonia Norris et al. VIRAL IMMUNOLOGY
- Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
- (2010) M. R. Green et al. BLOOD
- PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1
- (2010) M. Ghiotto et al. INTERNATIONAL IMMUNOLOGY
- Intensified Chemotherapy and Dose-Reduced Involved-Field Radiotherapy in Patients With Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD11 Trial
- (2010) Hans Theodor Eich et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- (2010) Julie R. Brahmer et al. JOURNAL OF CLINICAL ONCOLOGY
- Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma
- (2010) Andreas Engert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma
- (2009) S. M. Ansell et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation
- (2008) A. Bashey et al. BLOOD
- PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma
- (2008) R. Yamamoto et al. BLOOD
- Managing relapsed and refractory Hodgkin lymphoma
- (2008) Pauline Brice BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Safety and Pharmacokinetic Study of CT-011, a Humanized Antibody Interacting with PD-1, in Patients with Advanced Hematologic Malignancies
- (2008) R. Berger et al. CLINICAL CANCER RESEARCH
- Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: Tumor and microenvironment
- (2008) Eric D. Hsi LEUKEMIA & LYMPHOMA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started